Immusoft Obtains $2,739,999 New Funding

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    454 N 34th St. Seattle, WA 98103 USA
  • Company Description
    Immusoft’s mission is to develop a breakthrough autologous cell therapy platform for treating a variety of human diseases through our proprietary Immune System Programming (ISP™) technology. ISP™ technology can effectively re-program a patient’s own cells to become miniature drug factories in the body.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    Proceeds purposes were not disclosed. 11 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
  • M&A Terms
  • Venture Investor

Trending on Xconomy